Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.
Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, Nakaseko C, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Okamoto S, Oritani K, Okada M, Usui N, Nagai T, Amagasaki T, Wanajo A, Naoe T.
Usuki K, et al. Among authors: ohyashiki k.
Int J Hematol. 2012 Apr;95(4):409-19. doi: 10.1007/s12185-012-1026-9. Epub 2012 Feb 23.
Int J Hematol. 2012.
PMID: 22359103
Clinical Trial.